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Abstract 
Background: Antimalarial treatment and strategies have changed much in the last 15 years, 
resulting in an increased variety of medicines available. Active pharmacovigilance methods are 
important for continued safety surveillance of these medicines, particularly in environments in which 
there is variability in treatments prescribed and limited confirmatory diagnostic capacity as well as 
limited ability of spontaneous reporting pharmacovigilance systems to generate much needed safety 
information quickly and efficiently.  
Objective: To use the cohort-event monitoring (CEM) technique to gather drug utilisation and 
adverse event data for patients prescribed antimalarial medicines in an outpatient setting. 
Methods: The characteristics of a large urban African cohort of outpatients (n=2,831) receiving 
antimalarial medications are described. The cohort was actively surveyed over the subsequent week 
to record adverse events, using follow-up phone calls, paper reports and/or voluntary return clinic 
visits. Adverse events reported in the cohort were analysed overall and by clinically-relevant age and 
medication groupings.  
Results: At least one event was reported in 29.5% of patients. Adverse events were more likely to be 
reported in subjects older than 12 years of age, and by patients prescribed an artesunate-amodiaquine 
combination. A range of adverse events were reported, the most frequent higher level terms being 
asthenic conditions (10.1% of total cohort), neurological signs and symptoms (4.5%), headaches 
(3.1%), appetite disorders  (2.1%) and disturbances in consciousness (1.6%). There were three 
reports of possible extrapyramidal events (2 cases of tremor “hand and back shaking all over” and 
one case of tongue protrusion), which may appear to be related to combinations including 
amodiaquine and an artemisinin.  
Conclusion:  
The use of the CEM methodology is a useful tool for monitoring the safety of widely available and 
utilised medicines, particularly in an urban environment where spontaneous reporting yields poor 
results and where the availability of various regimens and high levels of medicine usage can give 
valuable ‘real-life’ safety data. The types and frequencies of events reported reflected the types of 
events expected in patients prescribed antimalarials and nearly all events reported are listed in the 
summary of product characteristics of the medicines involved.   
 
Word Count: 341  
 
 
Key points: 
1. Cohort event monitoring provides rapid real-life information on antimalarials as used in 
outpatient settings  
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2. Several adverse events reported after intake of antimalarial are similar to malaria symptoms 
necessitating large studies to identify real antimalarial associated events 
3. Rare but important events e.g. extrapyramidal symptoms can be picked up during cohort 
event monitoring  
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Word Count: 5,796  
 
1 Introduction 
 
The last 15 years have seen a large change in the treatment strategy for malaria, particularly in sub-
Saharan Africa. Rapidly rising drug resistance to standard treatments such as chloroquine and 
sulphadoxine-pyrimethamine and the consequent increase in morbidity and mortality has driven the 
development of a class of anti-malarials which combine artemisinin derivatives with long-acting 
partner drugs (artemisinin combination therapies- ACTs). [1,2] Due to the urgency of the situation, 
these new treatments have been widely deployed following pivotal trials demonstrating their efficacy 
and safety. [3-6] 
 
This widespread introduction of ACTs provided an opportunity to pilot pharmacovigilance systems 
to assess safety in geographical populations within whom the medicines may not yet have been 
tested during the pre-marketing clinical trials. In addition, the focus of clinical trials on ACTs in 
Africa has been in children, as this population is at the highest risk of serious morbidity and 
mortality .[7] As a result, limited information is available on the adverse event profile in older 
children and adults and in children under 6 months of age. Pharmacovigilance data collected during 
post-marketing surveillance will therefore be important to fill this knowledge gap especially since 
the antimalarial trials in children under 5 are often powered to determine efficacy and the occurrence 
of frequent adverse events. Rarely are such studies powered to detect less common safety issues. In 
Ghana, the first-line treatment for malaria was changed by the Ministry of Health to artesunate-
amodiaquine (ASAQ) in January 2005, and a cohort-event monitoring (CEM) study was designed to 
describe events following the use of anti-malarials and to explore the use of CEM methodology in 
this context. 
 
Cohort-event monitoring is an adaptation of prescription-event monitoring (PEM), in which patients 
who are prescribed a drug are actively followed-up to gain information on adverse events (AEs) 
which occurred in an appropriate time-frame following treatment. [8] CEM, just like PEM, is 
therefore a form of active surveillance. In PEM studies, exposure and event data is collected directly 
from health professionals who have direct access to patient healthcare records, often extending over 
many years of the patients life. However, in countries such as Ghana, the majority of outpatient 
records, where they exist, are only in paper-format (electronic health records are all but absent) and 
held by the patients due to the fluidity of accessing healthcare from different providers, for example 
independent drug shops in addition to government or private health centres. CEM is therefore 
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adapted to source event data directly from patients, through direct patient contact or provision of 
patient reporting systems.  
 
The pattern of drug utilisation observed in this setting in the CEM study and predictors of 
prescribing patterns have been described in an earlier paper. [9] This paper focuses on the safety data 
reported from this study, focussing on adverse event reports collected from patients who had 
received anti-malarial medicines from a prescription presented at a health facility pharmacy. The 
objective of the study was to capture adverse events to antimalarials when prescribed for the 
treatment of uncomplicated malaria in the community setting, through active procedures (CEM), 
which would illustrate the range and frequency of adverse events experienced by a naturalistic 
cohort following malaria treatment. The study also underlines the robustness of CEM methodology 
in monitoring safety of newly marketed community-prescribed medicines in such an environment 
and yields valuable information on the range and extent of events reported to individual antimalarial 
medicines.  
 
 
2 Methods 
Data presented in this article were collected between April and November 2006 through a 
prospective, longitudinal, observational cohort-event monitoring study in Accra and its environs in 
the Greater Accra Region of Ghana. The study source population covered approximately 4 million 
inhabitants (approximately 20% of the Ghanaian population at the time). The procedures for the 
recruitment and consenting of health centres and patients have been already described elsewhere. [9] 
In brief, 24 health institutions across Accra recruited patients prescribed anti-malarials consecutively 
from the pharmacy at the time of dispensing. 15 of these facilities were government hospitals/clinics 
whilst the rest were either private or quasi-government. Data collection at recruitment included 
demographics, contact details, method of diagnosis of malaria (health professional type and 
parasitological confirmation), anti-malarials prescribed and concomitant medications prescribed. As 
pointed out previously, [9] the original study design changed from a comparative study of the safety 
of artesuante-amodiaquine vs. chlorproguanil-dapsone; to a general descriptive study of the safety 
profile of prescribed anti-malarials due to WHO policy recommendations on treating uncomplicated 
malaria only with artemisinin-based combination therapy and the subsequent termination of the 
original study by the sponsor, WHO-TDR, in line with the WHO recommendations 
 
2.1 Methods of surveillance 
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Two types of follow-up mechanisms were employed in this CEM study – active follow-up by phone 
or self-reporting by patients either directly to the study team or to the Outpatients Department of the 
Korle-Bu Teaching Polyclinic, a site dedicated for managing all adverse events occurring in patients 
taking part in the study from the day of recruitment and until 28 days later. Active follow-up was 
performed by trained research assistants by primarily telephone contact and some limited home 
visits to the patient, within 7 days after drug dispensing. Some patients had to be called more than 
twice as the contact phone number given belonged to a friend/relative/co-tenant who may not have 
been available at the time the call was made.  Self-reporting to the research team or the Polyclinic 
was facilitated as follows. Each recruited patient was given a card which identified him/her as a 
participant in the study and thus eligible for free management at the Polyclinic from the day of 
recruitment till 28 days after (see Electronic Supplementary Material 1). A protocol for receiving 
and managing these patients and sending reports of their visit to the study team was also 
disseminated to all physicians and health workers at the Polyclinic. The card also had contact 
telephone numbers of key members of the study team for patients to call if needed. Patients were 
asked to report any events of medical concern (literally “anything that worries you”) at any time 
during the 7 day follow-up whether or not they thought that the event could be due to the medicine. 
Six telephone lines were dedicated to the project and maintained by the study team, to which the 
patients could call or send a text message (to a cell phone) and then were immediately responded to 
by the research assistants. Patients were also advised to return to the facility from which they 
obtained the initial treatment in case of concern, (for example lack of improvement in their clinical 
condition or suspected adverse events) and also had the option of seeing research staff at the pre-
defined treatment centre, i.e. the Korle-Bu Polyclinic. Patients were asked to report immediately to a 
health centre if they experienced any of the following signs: dark-coloured urine, rashes, sore throat, 
bruising or bleeding from any part of the body. Dark-coloured urine is a sign of haemolysis and the 
study team was keen to ensure that any patient with signs suggestive of haemolysis or any other 
serious event was promptly identified and managed appropriately. Patients requiring hospitalisation 
were given optimum care for their condition in line with the prevailing standard of care in Ghana. 
All such patients were managed by physicians at the Korle-Bu Polyclinic or the adjoining Korle-Bu 
Teaching hospital. Patients who suffered serious adverse events were followed up to determine 
outcome and any report of death investigated including results of autopsy. The study protocol for 
this study defined “serious adverse events” as those that result in death, are life-threatening, require 
in-patient hospitalisation or prolongation of existing hospitalisation, result in persistent or significant 
disability or incapacity, or is a congenital anomaly/birth defect.  
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The study team developed a standard method for obtaining information from patients by phone and 
used a structured questionnaire modelled along the national spontaneous reporting form for 
collection of safety events post-treatment. Information was collected concerning the prescribed 
medications (posology, dates of treatment start and stop, source of drug), adverse events (description 
of event, date of onset, date of cessation, treatment or action taken, outcome (including death), 
previous use of the drug and any similar AEs), concomitant medications, other available details (e.g. 
past medical history, laboratory test results, allergies) (see Electronic Supplementary Material 2). 
The research team visited each participating institution twice every week to collect recruitment 
forms, information on spontaneous reports received and discuss study progress. 
 
During the study period, additional community activities designed to increase awareness of the study 
and to promote reporting of adverse events through the national spontaneous reporting system were 
carried out; for example a short generic pharmacovigilance advertisement on Ghana TV, radio and 
newspapers, and logos and contact information were displayed on project vehicles.  
 
2.2 Data management 
Data were double-entered and verified on a Microsoft Access database (Microsoft Office 2003) and 
analysed using Stata (Version 10.1). Adverse event data was recorded according to how the patient 
or caregiver described the event, and then reviewed and coded using Medical Dictionary for 
Regulatory Activities (MedDRA®) (Version 13.1) terminology. MedDRA® the Medical 
Dictionary for Regulatory Activities terminology is the international medical terminology 
developed under the auspices of the International Conference on Harmonization of 
Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). 
MedDRA® trademark is owned by the International Federation of Pharmaceutical 
Manufacturers and Associations (IFPMA) on behalf of ICH. 
 
2.3 Analyses 
Treatments were grouped into four main categories – artemisinin-based monotherapy (monotherapy 
ART, where ART is used as an abbreviation for artemisinin), non-artemisinin based monotherapy 
(monotherapy non-ART), artesunate-amodiaquine (ASAQ) and other artemisinin-combination 
therapies (ACTs). Univariate analyses using crude odds ratios (OR) were applied to describe the 
determinants of event reporting. In addition, multivariate analysis was conducted using logistic 
regression (reported as adjusted odds ratio (AOR) and 95% Wald Confidence intervals (CI)) to 
investigate the combined effect of patient characteristics in relation to whether or not events were 
reported. Variables significant at p<0.1 in univariate analyses were included in the logistic 
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regression model. Frequency of event reporting was also assessed and reported as percentages of 
treatment group. All events reported were grouped by MedDRA® higher level term (HLT) 
according to age group and therapy type. Events reported in patients under 5 years were grouped by 
treatment prescribed (amodiaquine; artemether; artemether+amodiaquine; artesunate; 
dihydroartemisinin; dihydroartemisinin+amodiaquine; artesunate+amodiaquine) and reported at 
MedDRA® preferred term (PT) level. Adverse events verbatim as reported by the patients or 
caregiver were also reviewed qualitatively. 
 
Events that existed prior to treatment were not collected and there was no attempt to distinguish 
between new or worsening events in individual patients or the study cohort as a whole. All events 
recorded post-treatment were analysed statistically to determine the likely factors associated with the 
occurrence of adverse events following antimalarial treatment. There was no case-causality or 
relationship assessment of events reported as there were no obvious benefits of this exercise in the 
current study design. 
 
2.4 Ethics 
The study was approved by the Ethical and Protocol Review Committee of the University of Ghana 
Medical School. Patients were included in the study following signed and witnessed informed 
consent. A parent/guardian provided consent for patients under the age of 18 years. 
 
3 Results 
3.1 Cohort composition 
Twenty-four health centres recruited patients for the study, resulting in a cohort of 2,831 eligible 
patients. The distribution of the baseline characteristics of the cohort and prescribing patterns are 
described fully in a previous paper, [9] and the type and frequency of anti-malarials prescribed are 
given in Table 1. Demographically, the recruited cohort included 59.9% (n=1,695) females, with 
increasing female numbers with increasing age. Children under 5 years comprised 21.6% (n=610) of 
the cohort, 11.2% (n=317) 5-12 years, 60.6% (n=1,716) 13-59 years and 5.5% (n=157) 60 years and 
above (1.1%, n=31, of unknown age). A total of 2,092 (73.9%) patients were followed-up after 
treatment. Figure 1 shows the distribution of patients by treatment group and the number in the 
cohort with a follow-up contact and at least one event reported. The distribution of characteristics of 
patients followed-up was similar to the baseline cohort. Paediatric patients (defined as age 12 years 
and below) comprised 31.6% (n=662) of followed-up patients. The female population of the cohort 
was 58.5% (n=1,224) and approximately 90% (n=1,882) of all prescriptions were resulting from a 
clinical diagnosis of malaria based on clinical signs and symptoms alone with no parasitological 
confirmation. Concomitant antibiotics were prescribed to 30.5% (n=639) of patients, clearly 
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indicating a high proportion of presumptive treatment of fevers for both malaria and possibly other 
infections contrary to national guidelines.  
 
3.2 Reporting of events 
Table 2 shows the results of univariate analysis and multivariate logistic regression to determine 
factors associated with the reporting of AEs. Results presented in the table indicate that the age 
group, treatment arm (anti-malarial drug administered) and concomitant antibiotic administration 
were associated with the report of AE in the univariate analyses. In the multivariate analysis, the 
odds of reporting AEs were more in subjects older than 12 years of age (AOR, 1.56 [95% CI, 1.24 – 
1.96], p<0.001) compared with children <5 years. The odds of patients prescribed ASAQ to report 
an event was also higher (AOR, 1.51 [95% CI, 1.22- 1.87], p<0.001) compared with those prescribed 
non-artemisinin monotherapy (Table 2). Non-ASAQ ACTs showed a borderline association with 
event reporting (AOR 1.35 [95% CI, 0.98-1.86], p=0.063) compared with non-artemisinin 
monotherapy. There was no significant difference in reporting between males and females, mode of 
diagnosis (presumptive versus laboratory confirmed) or number of concomitant medications 
prescribed. Concomitant prescription with antibiotics was significantly associated with reporting of 
events in the univariate analysis, but not when adjusting for factors included in the multivariate 
analyses. 
3.3 Description of reported events  
At least one event was reported in 29.4% (n=616, [95% CI=27.5-31.5]) of patients who were 
successfully followed up. The majority of events did not require discontinuation of anti-malarial 
therapy and were resolved without additional treatment. A large proportion of reported events, 
including asthenia, nausea and vomiting, headache, lack of appetite, dizziness, fever, diarrhoea, 
musculoskeletal pain and cough were mild in intensity and overlapped with known malaria signs and 
symptoms. Commonly reported events also included undesirable effects known to be associated with 
certain anti-malarial therapies, for example asthenia, vertigo, sleep disturbance, pruritus, sensory 
abnormalities and rashes. [10] There was one death during follow-up of an adult male (aged 35 
years) who had been prescribed ciprofloxacin in addition to ASAQ antimalarial therapy. Post-
mortem results indicated that the patient died of complications related to typhoid fever. 
The most commonly reported event was asthenia, often described by patients as ‘weakness’ or 
‘generalized weakness’ (n=211, 10.1% of the follow-up cohort, [95% CI= 8.8-11.5]) (Table 3). The 
odds of reporting asthenia was higher in patients prescribed ASAQ compared with patients 
prescribed non-ASAQ ACTs (AOR, 1.69 [95% CI, 1.02-2.86]), artemisinin monotherapy (AOR, 
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2.17 [95% CI, 1.49-3.13]) or non-artemisinin monotherapy (AOR, 5.26 [95% CI, 1.92-14.29]). 
Asthenia was also associated with females more than with males (AOR 1.57 [95% CI, 1.13-2.18]).  
 
The profile of reported events for ASAQ as the new first-line therapy at the time of the study was 
similar to that of other available treatments (Table 3). Of particular interest for the safety profile of 
this therapy are events of the nervous system. One case of paraesthesia (an event labelled as 
uncommon in the current Summary of Product Characteristics) was reported in a 46 year old male 
who was prescribed ASAQ concomitant with amoxicillin, paracetamol and chlorpheniramine (an 
antihistamine). Two reports of tremor were also reported in adult females (verbatim ‘back and hand 
shaking’, ‘shaking all over’), and one dyskinesia (verbatim ‘tongue protrusion’), reported together 
with tongue swelling. 
 
Cardiac events reported included 10 reports of palpitations (6 in the ASAQ group). One adult patient 
on ASAQ experienced dizziness, collapsed and later recovered. No events diagnosed as hepatic 
toxicity were reported. Seven patients reported chromaturia (mapped to the Higher Level Term 
“Urinary abnormalities” in Table 4) – three aged <5 years (two ASAQ patients, one non-ASAQ 
ACT patient) and four adults (two ASAQ patients and two artemisinin monotherapy patients). 
Ocular icterus was reported in a patient under 5 years (non-ASAQ ACT) and an adult on artemisinin 
monotherapy (mapped to the Higher Level Term “Ocular disorders NEC” in Table 4). 
 
The most commonly recorded events in patients under 5 years of age taking ASAQ (n=113) included 
general weakness (n=16, 14.2%, [95% CI=8.3-22.0]), vomiting (n=9, 8.0%, [95% CI=3.7-14.6]), 
anorexia (n=8, 7.1%, [95% CI=3.1-13.5]) and pyrexia (n=7, 6.2%, [95% CI=2.5-12.3]) in single 
episodes (Table 5). There was one report of pharyngolaryngeal pain (event occurred two days after 
commencement of treatment) in a boy aged 1 year 3 months who was administered ASAQ in 
addition to an antitussive and an antibiotic. One case of urticaria was reported in a 1 year-old boy 
prescribed ASAQ in addition to paracetamol and haematinic (event occurred on the same day of 
commencement of treatment). 
 
Whilst a dihydroartemisinin (DHA)+AQ regimen was not commonly prescribed among the study 
cohort, some notable reactions were reported with DHA+AQ including loss of consciousness in a 1 
year 8 months old female who was also prescribed antitussive, flucloxacillin and paracetamol (event 
occurred the same day of commencement of treatment). Skin discolouration as an event was reported 
to have occurred on the same day of start of drug administration in two female patients (aged 3 years 
and 1 year 4 months) who were both prescribed DHA+AQ in addition to paracetamol, folic acid plus 
oral rehydration salt in the 1
st
 case and amoxicillin plus antitussive in the 2
nd
 case. 
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Two cases of swollen eyes were reported (both events occurred a day after starting drug treatment) - 
the first case involving a 4 year old male patient prescribed artemether + AQ in addition to 
paracetamol and haematinic and the second case involved a 6 years old female prescribed only 
artemether. One case of musculoskeletal stiffness was reported (on the same day of start of drug 
administration) in a 16 year old female prescribed ASAQ plus paracetamol and haematinic. 
 
3.4 Reports to hospital clinics 
During recruitment, patients were given special cards with which they could access free medical care 
in the event of adverse events. Many of the adverse events reported during the follow-up calls had 
subsided at the time of the calls. Patients who were still experiencing adverse events at the time of 
follow-up calls were urged to report to Korle-Bu Polyclinic, the designated study clinic, for 
treatment. There were 60 patients who reported to the Out-Patients Department (OPD) of the Korle-
Bu Polyclinic due to suspected adverse events (Table 6). There were 27 (3.1%) ASAQ patients who 
attended the hospital, 28 (3.1%) monotherapy patients and 5 (1.6%) who had taken non-ASAQ 
ACTs. In general, these patients felt they had events which were related to the anti-malarial intake 
which prompted the hospital contact. The most common event reported by the ASAQ patients to the 
Polyclinic was abdominal pain or discomfort reported by 11 patients (40.7%, [95% CI=22.4-61.2]). 
Palpitations were reported by 3 patients (11.1%, [95% CI=2.4– 29.2]) out of the 27 patients on 
ASAQ therapy who came to the Polyclinic. No neutropaenia was detected for any patient reporting 
to hospital though it must be stressed that few of the patients had laboratory investigations. All the 
patients reporting to hospital recovered fully without sequelae. The data from these patients are 
incorporated into the general analysis and such routine hospital attendance was not classified as 
“hospitalisation” and thus not considered “serious” events unless the events satisfied other criteria of 
“serious events” as defined in the methods section.  
 
3.5 Qualitative aspects of event reports 
Features of the verbatim reports from the patients provide indicators of the severity of the event, and 
could give clues as to the possible causality of events. For example, adult patients reported to 
research assistants that the type of ‘weakness’ they experienced after drug administration was quite 
different from the ‘weakness’ they associated with uncomplicated malaria. Temporality information 
can also add important context for causality assessments, for example ‘felt dizzy and vomiting each 
time drug was taken’, ‘feeling of weakness after each dose of the drug’, ‘weak and has to sleep and 
then eat to become strong again (happens any time drug is taken)’. Culturally-based descriptions also 
required interpretation in context, for example ‘headache, feeling dizzy in the sun, back, hand 
shaking, feet and hands feel heavy, sometimes stiffness’.  However, most of the reported events were 
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possible to code directly and accurately using MedDRA®. Where it became necessary, complex 
culturally-based descriptions were broken down into groups of events and coded using MedDRA®. 
 
4 Discussion 
This study demonstrated that it is feasible to perform active safety monitoring, in this case CEM, as 
part of the pharmacovigilance activities in an urban African setting. The combination of actively 
solicited event data combined with the opportunity for patients to spontaneously report, elicited a 
large volume of event reports which reflects the safety of anti-malarials in real-life usage. Cohort 
event monitoring in sub-Saharan Africa has the potential to become an important tool in 
pharmacovigilance since the passive/spontaneous reporting rate is generally low. Some documented 
advantages of CEM include: a) effective in identifying signals at an early stage; b) ability to make 
accurate comparisons between medicines; and c) provides clinically significant results rapidly and 
hence stimulates interest in drug safety in general. [11]  
 
4.1 Patterns of reporting 
Adverse events were reported across age groups, with a higher rate of reporting in adults, who were 
also the group most likely to be prescribed ASAQ in this cohort. At the time of the study, ASAQ had 
recently been designated the first-line medication for treating uncomplicated malaria in Ghana, and a 
number of adverse events were widely reported in the media. Subsequently, a review of the ASAQ 
dosing regimen and inclusion of artemether + lumefantrine (AL) and dihydroartemisinin + 
piperaquine as additional first-line medications occurred. These actions may have made patients 
taking ACTs more attentive of their response to treatment, compared to non-ACTs – a situation 
similar to the well-known Weber effect. [12]  
 
4.2 Adverse events 
The most commonly reported events included asthenia, nausea and vomiting, headache, lack of 
appetite, abdominal pain, dizziness, fever, pruritus, increased temperature, diarrhoea, 
musculoskeletal pain and cough. These are commonly reported symptoms of clinical malaria, and 
thus could be indication-related events, and are similar to those reported in the recent CEM cohort 
performed in Nigeria. [13] Knowledge of clinical signs and symptoms at baseline could have 
assisted in distinguishing whether these events occurred newly after antimalarial administration or 
were associated with the diagnosis. Current CEM studies therefore collect baseline events. However, 
such data collection may not be feasible in all CEM studies, and therefore alternative methods of 
analysis need to be explored to determine whether such symptoms are presented in excess of what 
would be expected as a result of malaria morbidity. Comparative CEM studies with large numbers 
and different ACTs will thus yield valuable information in this regard as would meta-analyses of 
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individual CEM studies though the extremely low numbers of published studies precludes the latter 
option presently. No events of neutropaenia were reported in all the treatment groups. However, 
non-specific symptoms associated with neutropaenia due to amodiaquine toxicity, namely fever, 
lethargy, sore throat and weakness, were observed in patients prescribed amodiaquine either as 
monotherapy or as artemisinin combination therapy, but were not further investigated in the 
laboratory. Routine laboratory investigations for events such as this would be expensive to 
implement on a routine basis during pharmacovigilance activities, but an algorithm of event severity 
and risk could perhaps be considered in similar studies in the future. The cardiac events noted in the 
cohort, particularly in ASAQ patients, have been highlighted as a potential risk in a previous 
electrocardiogram study demonstrating increased risk of bradycardia on the second day of treatment 
with ASAQ. [14] Dystonic effects associated with amodiaquine+artesunate have, since the study 
concluded, been published as a signal of adverse events to amodiaquine-containing ACTs. [10] 
Interestingly, this signal represents the first drug-safety signal to be published from Africa based on 
data obtained solely from African passive spontaneous reporting systems. The summary of product 
characteristics (SPC) of amodiaquine+artesunate combinations has now been amended to include 
dystonia as a possible adverse reaction. The 2 reports of tremor reported in adult females (‘back and 
hand shaking’, ‘shaking all over’), and one report of dyskinesia (verbatim ‘tongue protrusion’) 
appear to fit within the general definition of dystonic events and adds to the growing body of 
evidence linking ASAQ to movement disorders.  
 
Overall, events reported were within the expected type and frequency based on the summary of 
product characteristics of the medications prescribed and from other literature. 
 
 
4.3 Limitations 
Overall, the cohort size was not large enough to be able to detect rare events (occurring in ≥ 0.01% 
and < 0.1% of the population treated). The sample size of just under 3000 would thus be expected to 
record only events occurring at or more than rates of 1 in 1000. The proportion of patients lost to 
follow-up in the study was relatively high (26.1%) but this is not unusual in studies of this nature 
and compares favourably with results obtained in other studies carried out in Ghana with similar 
methodologies. [15,16] It highlights one of the challenges in retaining a large cohort of patients in 
such an environment where certain population groups may have less access to telecommunications, 
and homes may be difficult to locate in the absence of established demographic data. This may have 
introduced bias in reporting as those less likely to have telephone availability could have been in 
particular socioeconomic or educational groups which could also be related to treatment options and 
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also event-reporting characteristics, although there does not appear to have been any 
disproportionate loss to follow-up in terms of age, gender or proximity to the designated healthcare 
centre for hospital reports. There are virtually no electronic health records in Ghana thus classical 
PEM studies could not have been undertaken. This observational study was also not blinded, and 
therefore both the reporter and the data collector were aware of the treatment taken, and may have 
prompted additional reporting according to knowledge of the regimen. However, reporting of many 
common events which could also be related to malaria, such as nausea and vomiting, was fairly 
consistent across treatment and age groups.  
 
 
One of the ways in which event reporting in PEM and some CEM studies differs from those in 
clinical trials is that it is not possible to determine baseline events in these large observational 
studies, and therefore events which are reported may or may not be truly ‘new’ events. This has an 
impact on considerations of causality of events in relation to the medicine, and may also mean that 
indication-related events appear at a high rate during the observation period, although these may 
have been present prior to treatment. In view of these limitations and considering the study design, 
case-causality assessment was not undertaken for individual events.  
 
Pharmacovigilance is further complicated by lack of resources to definitively diagnose malaria or 
treatment practices where practitioners refuse to diagnose malaria using rapid-diagnostic tests or 
microscopy contrary to national or international guidelines. The high level of antibiotic prescribing 
(30.8%) coupled with the clinical rather than microscopical diagnosis of malaria [9] may indicate 
uncertainty in diagnosing the cause of the presenting complaints, especially fever, and hence an 
attempt to treat both for malaria and any suspected underlying infection(s). Medication use in adults 
without a definitive malaria diagnosis could also result in events related to un-investigated or 
undiagnosed alternative conditions, and therefore pharmacovigilance reports may also reflect burden 
and complications from other diseases, rather than medication-related events.  Clinicians likely to 
have only one contact with a patient, especially for whom there is a possibility that they have a 
disease which can be fatal if untreated, are likely to treat all potential causes even though current 
WHO guidelines and national malaria treatment policies clearly indicate the need to test before 
treating except in rare situations where testing facilities are not available. Presumptive diagnosis and 
treatment of malaria with multiple medicines and antibiotics is not uncommon in most malaria 
endemic countries in Africa [9, 17], but the practice poses challenges for safety monitoring and case 
causality assessment as reported events could reflect aspects of a combination of diseases, drug-drug 
interactions or drug-related events. For example, reported rashes may be interpreted as a sign of 
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hypersensitivity to medication, but could also reflect symptoms of viral infection. This is, however, 
‘real life medical practice’ in Africa, and needs to be considered when assessing the safety profile of 
medicines in the community setting. The current WHO malaria treatment guideline which strongly 
recommends testing using microscopy or rapid diagnostic tests before treating malaria may go a long 
way to improve availability of diagnostic aids and thus reduce the presumptive treatment of malaria 
in Africa though there is no published evidence that this is actually happening yet. 
 
Previous antimalarial therapies taken within the past month were not recorded. Data on repeat 
courses of curative doses of antimalarials is scarce, but this is key information for 
pharmacovigilance activities, particularly as previous adverse experiences with particular treatments 
may have also influenced the choice of a current treatment and may indicate a particular 
susceptibility to certain adverse reactions. Since this study was non-interventional and did not 
require laboratory investigations post-treatment, it might miss important events like anaemia that 
may occur up to 2 weeks after treatment. Identification of such events may require other study 
designs though the routine deployment of electronic health records (see section 4.5) could facilitate 
identification of such important signals.  
 
4.4 Applicability 
It is likely that the design of this study would be more difficult to replicate in an area with a more 
sparsely distributed population with less telecommunications networks coverage and access to 
electronic media. Prescribing practices in urban areas, and therefore likely event reports, are likely to 
differ from rural areas, in part due to availability of medications, diagnostic equipment and level of 
health worker expertise. However, with expanding mobile networks throughout the continent, the 
potential for such a follow-up model to be feasible over a wider geographical area is on the horizon. 
 
4.5 Costs of technique and benefits 
This study has demonstrated the benefits of active follow-up studies like CEM in collecting large 
amounts of safety data quickly in the period immediately following the deployment of a new 
medicine, vaccine or treatment regimen. Such data is useful for policy makers, programme managers 
and patients alike as it permits rapid assessment of real-life safety of products. A large cohort size of 
10,000 is however needed in order to detect events occurring at or more frequently than 1 in 3000. 
Such large cohort sizes comes with a cost component which may nonetheless prove cost-effective. 
The cost of initiating a new CEM study in Africa is anywhere between US$75000 – US$100,000 
including cost of a vehicle, equipment, consumables, staff and patient management costs in case of 
adverse events. These studies are non-interventional and the costs do not include laboratory 
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examinations except in cases of adverse events. Subsequent studies may cost less as the equipment 
and vehicles could be re-used. This relatively high cost is however justifiable when one considers 
that the routine spontaneous reporting systems employed by nearly all malaria-endemic countries 
yield very little results in terms of adverse reaction reports to antimalarials in particular [18] and all 
medicines in general. Newer approaches like the routine use of electronic health records may offer 
cost-effective means of collecting long-term data on the safety of antimalarial in real-life usage. The 
deployment of electronic health records, even in just a few sentinel clinics or hospitals, will also go a 
long way to strengthen existing health systems in malaria-endemic countries and provide the much 
needed baseline information on diseases and events often absent in most phase IV studies conducted 
in Africa. It will also provide longitudinal data that may lend themselves to epidemiological analysis 
as well as comparison of future studies with current data.  
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Conclusions 
The profile of adverse events recorded in this study following prescription of antimalarials for 
uncomplicated malaria were similar to the symptoms of malaria. The most commonly reported event 
was asthenia, often described by patients as ‘weakness’ or ‘generalized weakness’ This was reported 
more frequently in patients prescribed ASAQ and was also more associated with females more than 
with males. There were three cases of dystonic reactions (reported as “back and hand shaking” in 
two cases and “tongue protrusion” in one case). There were 10 reports of palpitations and 7 reports 
of chromaturia. The findings in this study lay the ground for larger comparative studies of the real-
life safety of antimalarials in general and ACTs in particular, especially in the current era of multiple 
ACTs. The study shows that cohort-event monitoring (CEM) implemented in an urban community is 
a feasible active safety monitoring approach to reinforce pharmacovigilance activities. The 
combined follow-up model, including active phone interviews, spontaneous patient reporting and the 
option for return to the prescribing clinic/hospital, enriches the quality and completeness of the data, 
and should be recommended practice. With regards to the safety data obtained from this CEM study, 
the safety profile of the drugs under monitoring is consistent with safety profile expected for the 
medicines concerned. This study has also added to the growing body of evidence linking 
amodiaquine-based regimen with movement and/or dystonic adverse events. 
 
Several challenges were identified throughout the study that, once addressed, can improve CEM in 
these settings. These include: i) improving malaria diagnostic test availability, ii) expansion of 
information technology and telecommunications capacity and general infrastructure, iii) knowledge 
and understanding of local and cultural context of patient-reported events, iv) improving cohort 
retention and minimize loss to follow up by leveraging media channels and diversify individual 
reminders channels. Given the complexity and flexibility of prescribing patterns, it is also apparent 
that the capacity and sustainability of pharmacovigilance projects can be enhanced by widening the 
scope of monitoring beyond a single disease or drug. International collaboration, both with the WHO 
and the Uppsala Monitoring Centre (UMC) in Sweden as well as across regions in Africa can also 
augment the feasibility and value of the safety information acquired. Studies such as these will 
complement the dearth of information on the real life safety of antimalarials. [18] The well known 
drawbacks of spontaneous reporting, typically under-reporting, is likely to be worse in resource-
constrained environments and pharmacovigilance studies such as this will increasingly become the 
main source of Phase IV drug safety information.  
 
There are many areas that can therefore be identified for future research, both around the methods of 
collection of adverse event data in this context, its transferability to a more rural environment, and 
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also the type of data collected. Benefits of educating medicine-users and prescribers to acknowledge 
the potential harms of medicines and report concerns could impact on both service user and 
prescriber behaviour, resulting in more rational drug use which may benefit the individual and have 
a wider-ranging public health benefit in the long term.    
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Figure 1.Patient flow 
 
 
 
a
Percentage of treatment group lost to follow-up 
b
Percentage of treatment group who were followed-up 
c
Percentage of patients followed-up who had an event according to treatment group 
d
Percentage of patients followed-up who did not have an event according to treatment group 
 
NOTE: percentage a + b = 100% for each treatment group 
 
Abbreviations: 
ART – artemisinin 
ASAQ – artesunate-amodiaquine 
ACT – artemisinin combination therapy
Baseline cohort - 2,831 patients 
ASAQ:    1,217 [342 (28.1%) ≤ 12 years] 
Non-ASAQ ACTs:   418 [280 (67.0%) ≤ 12 years] 
Monotherapy(ART-based):  936 [166 (17.7%) ≤ 12 years] 
Monotherapy(non-ART):  260 [139 (15.0%) ≤ 12 years] 
 
 
ASAQ: 336    (27.6%)
a
 
Non-ASAQ ACTs: 104    (24.9%)  
Monotherapy(ART-based): 215    (23.0%) 
Monotherapy(non-ART): 84      (32.3%) 
 
Lost to follow-up 
n=739 (26.1%) 
Followed-up 
n=2,092 (73.9%) 
Event reported n=616 (29.4%) (949 events) No event reported n=1,476 (70.6%) 
ASAQ: 302 (34.3%)
c
 
Non-ASAQ ACTs: 81   (25.8%) 
Monotherapy(ART-based): 201 (27.9%) 
Monotherapy(non-ART): 32   (18.2%) 
 
ASAQ: 579 (65.7%)
d
 
Non-ASAQ ACTs: 233 (74.2%) 
Monotherapy(ART-based): 520 (72.1%) 
Monotherapy(non-ART): 144 (81.8%) 
 
ASAQ: 881    (72.4%)
b
 
Non-ASAQ ACTs: 314    (75.1%)  
Monotherapy(ART-based): 721    (77.0%) 
Monotherapy(non-ART): 176    (67.7%) 
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Table 1. Anti-malarial treatment prescribed 
This table has been reproduced from reference [9] 
 
Drug group/treatment N (%) 
1st line therapy (ASAQ) 1, 217 (43.0) 
ACT-Other 418 (14.8) 
DHA+AQ 240 (8.5) 
Artemether+AQ 77 (2.7) 
Artemether+lumefantrine 58 (2.1) 
DHA+pyrimethamine-sulphametopirazine 13 (0.5) 
Artesunate+SP 12 (0.4) 
DHA+SP 6 (0.2) 
DHA+chloroquine 5 (0.2) 
Artesunate+chloroquine 3 (0.1) 
Artemether+pyrimethamine-sulphametopirazine 1 (0.04) 
Artemether+quinine 1 (0.04) 
Artesunate+ quinine 1 (0.04) 
DHA+artemether+lumefantrine 1 (0.04) 
Monotherapy-ART based              936 (33.1) 
DHA 577 (20.4) 
Artesunate 293 (10.4) 
Artemether 55 (1.9 
Artesunate/artemether  10 (0.4) 
Artemether/DHA 1 (0.04) 
Monotherapy – non ART 260 (9.2) 
Amodiaquine 133 (4.7) 
SP 78 (2.8) 
Pyrimethamine-sulphametopirazine 32 (1.1) 
Chloroquine 14 (0.5) 
Quinine 3 (0.1) 
Total 2831 
ASAQ= artesunate-amodiaquine; ACT= artemisinin  combination therapy ; ART= 
artemisinin; DHA = dihydroartemisinine; AQ = amodiaquine; SP = sulphadoxine-
pyrimethamine 
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Table 2. Patient characteristics in relation to whether one or more events were reported 
 
a
N=1923. Patients with unknown age (n=15) and/or unknown mode of diagnosis (n=148) were 
excluded from the multivariate analyses. Only variables significant at p<0.1 were included in the 
final model.  
 
Abbreviations: OR: odds ratio; CI: confidence interval; ART: artemisinin; ASAQ: artesunate-
amodiaquine; ACT: artemisinin combination therapy
 
Characteristic 
Event(s)  
N=616 n, (%) 
Univariate Analysis 
Crude OR [95% CI] p-value 
Multivariate
a
 Analysis 
Adjusted OR [95% CI] p-value 
Age Group 
<5 years (N=443) 
5- 12 years (N=219) 
>12 years (N=1,415) 
Unknown (N=15) 
 
 
106(23.9) 
46(21.0) 
460(32.5) 
4 (26.7) 
 
Ref 
0.84[0.57 – 1.25] 
1.50 [1.20 – 2.00] 
 
 
0.4 
0.001 
 
 
Ref 
- 
1.56  [1.24 – 1.96] 
 
 
 
<0.001 
 
Gender 
Male (N=868) 
Female (N=1,224) 
 
 
246(28.3) 
370(30.2) 
 
Ref 
1.10 [0.90 – 1.32] 
 
 
0.35 
--  
- 
- 
Mode of diagnosis 
Presumptive (N=1,882) 
Laboratory confirmed (N=63) 
Unknown (N=147) 
 
573(30.5)17(27.0) 
26 (17.7) 
 
 
Ref 
0.84 [0.48 – 1.49] 
 
 
0.56 
--  
- 
- 
 
Anti-malarial drug administered 
Monotherapy (Non-ART based) (N=176) 
Monotherapy (ART based) (N=721) 
ASAQ (N=881) 
Non-ASAQ ACTs (N=314) 
 
 
 
32(18.2) 
201(27.9) 
302(34.3) 
81(25.8) 
 
 
 
Ref 
1.74 [1.14 – 2.64] 
2.35 [1.56 – 3.53] 
1.56 [0.99 – 2.48] 
 
 
 
0.009 
<0.001 
0.056 
 
 
 
Ref 
- 
1.51  [1.22 – 1.87] 
1.35  [0.98 – 1.86] 
 
 
 
<0.001 
0.063 
Concomitant antibiotic administration 
No (N=1,453) 
Yes (N=639) 
 
447(30.8) 
169(26.5) 
 
Ref 
0.81 [0.66 – 0.99] 
 
 
0.046 
 
- 
- 
 
- 
- 
 
Number of concomitant medications 
prescribed 
3 or less (N=1201) 
4 and above (N=1630) 
 
 
 
256(28.0) 
360(30.5) 
 
 
 
Ref 
1.13 [0.93 – 1.36] 
 
 
 
 
0.214 
 
 
 
 
- 
 
 
 
 
- 
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Table 3. Events reported grouped by MedDRA® Higher Level Term (HLT) according to therapy type 
 
 
Total cohort ASAQ ACT other Monotherapy ART  Monotherapy non-ART 
 
N=2092 N=881 N=314 N=721 N=176 
MedDRA® Higher Level Term n(%) n(%) n(%) n(%) n(%) 
Anaemias NEC 1(0.05%) 1(0.11%) 0(0%) 0(0%) 0(0%) 
Anal and rectal signs and symptoms 1(0.05%) 1(0.11%) 0(0%) 0(0%) 0(0%) 
Anxiety symptoms 4(0.19%) 3(0.34%) 0(0%) 0(0%) 1(0.57%) 
Apocrine and eccrine gland disorders 1(0.05%) 0(0%) 0(0%) 1(0.14%) 0(0%) 
Appetite disorders 44(2.1%) 26(2.95%) 9(2.87%) 8(1.11%) 1(0.57%) 
Asthenic conditions 211(10.09%) 124(14.07%) 24(7.64%) 58(8.04%) 5(2.84%) 
Bladder and urethral symptoms 4(0.19%) 2(0.23%) 0(0%) 2(0.28%) 0(0%) 
Bone related signs and symptoms 2(0.1%) 1(0.11%) 0(0%) 1(0.14%) 0(0%) 
Breast signs and symptoms 1(0.05%) 0(0%) 0(0%) 1(0.14%) 0(0%) 
Breathing abnormalities 4(0.19%) 3(0.34%) 0(0%) 1(0.14%) 0(0%) 
Cardiac signs and symptoms NEC 10(0.48%) 6(0.68%) 0(0%) 3(0.42%) 1(0.57%) 
Circulatory collapse and shock 1(0.05%) 1(0.11%) 0(0%) 0(0%) 0(0%) 
Coughing and associated symptoms 9(0.43%) 4(0.45%) 2(0.64%) 1(0.14%) 2(1.14%) 
Dermal and epidermal conditions NEC 6(0.29%) 2(0.23%) 1(0.32%) 3(0.42%) 0(0%) 
Dermatitis and eczema 1(0.05%) 0(0%) 0(0%) 1(0.14%) 0(0%) 
Diarrhoea (excl infective) 25(1.2%) 12(1.36%) 7(2.23%) 4(0.55%) 2(1.14%) 
Disturbances in consciousness NEC 33(1.58%) 17(1.93%) 5(1.59%) 7(0.97%) 4(2.27%) 
Disturbances in initiating and maintaining sleep 14(0.67%) 7(0.79%) 3(0.96%) 1(0.14%) 3(1.7%) 
Dyspeptic signs and symptoms 13(0.62%) 10(1.14%) 0(0%) 3(0.42%) 0(0%) 
Ear disorders NEC 1(0.05%) 1(0.11%) 0(0%) 0(0%) 0(0%) 
Faecal abnormalities NEC 3(0.14%) 1(0.11%) 1(0.32%) 1(0.14%) 0(0%) 
Febrile disorders 20(0.96%) 11(1.25%) 1(0.32%) 5(0.69%) 3(1.7%) 
Feelings and sensations NEC 27(1.29%) 13(1.48%) 4(1.27%) 8(1.11%) 2(1.14%) 
Flatulence, bloating and distension 2(0.1%) 0(0%) 1(0.32%) 1(0.14%) 0(0%) 
Fluid intake decreased 1(0.05%) 0(0%) 0(0%) 1(0.14%) 0(0%) 
Gastrointestinal and abdominal pains (excl oral and throat) 40(1.91%) 15(1.7%) 7(2.23%) 13(1.8%) 5(2.84%) 
Gastrointestinal atonic and hypomotility disorders NEC 3(0.14%) 3(0.34%) 0(0%) 0(0%) 0(0%) 
Gastrointestinal signs and symptoms NEC 7(0.33%) 2(0.23%) 0(0%) 5(0.69%) 0(0%) 
General signs and symptoms NEC 2(0.1%) 0(0%) 1(0.32%) 1(0.14%) 0(0%) 
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Headaches NEC 65(3.11%) 26(2.95%) 9(2.87%) 26(3.61%) 4(2.27%) 
Heart rate and pulse investigations 1(0.05%) 1(0.11%) 0(0%) 0(0%) 0(0%) 
Increased physical activity levels 8(0.38%) 7(0.79%) 0(0%) 1(0.14%) 0(0%) 
Joint related signs and symptoms 3(0.14%) 0(0%) 0(0%) 3(0.42%) 0(0%) 
Lacrimal disorders 2(0.1%) 1(0.11%) 0(0%) 1(0.14%) 0(0%) 
Mental impairment (excl dementia and memory loss) 1(0.05%) 1(0.11%) 0(0%) 0(0%) 0(0%) 
Migraine headaches 2(0.1%) 2(0.23%) 0(0%) 0(0%) 0(0%) 
Muscle tone abnormalities 1(0.05%) 1(0.11%) 0(0%) 0(0%) 0(0%) 
Muscle weakness conditions 2(0.1%) 2(0.23%) 0(0%) 0(0%) 0(0%) 
Musculoskeletal and connective tissue pain and discomfort 10(0.48%) 5(0.57%) 0(0%) 4(0.55%) 1(0.57%) 
Musculoskeletal and connective tissue signs and symptoms NEC 1(0.05%) 0(0%) 1(0.32%) 0(0%) 0(0%) 
Nasal congestion and inflammations 1(0.05%) 1(0.11%) 0(0%) 0(0%) 0(0%) 
Nausea and vomiting symptoms 76(3.63%) 32(3.63%) 15(4.78%) 26(3.61%) 3(1.7%) 
Neurological signs and symptoms NEC 93(4.45%) 51(5.79%) 5(1.59%) 33(4.58%) 4(2.27%) 
Ocular disorders NEC 5(0.24%) 0(0%) 2(0.64%) 2(0.28%) 1(0.57%) 
Ocular infections, inflammations and associated manifestations 4(0.19%) 1(0.11%) 3(0.96%) 0(0%) 0(0%) 
Oedema NEC 2(0.1%) 1(0.11%) 0(0%) 1(0.14%) (0%) 
Oral soft tissue pain and paraesthesia 4(0.19%) 2(0.23%) 1(0.32%) 10(1.39%) 1(0.57%) 
Pain and discomfort NEC 30(1.43%) 18(2.04%) 1(0.32%) 0(0%) 1(0.57%) 
Paraesthesias and dysaesthesias 1(0.05%) 1(0.11%) 0(0%) 0(0%) 0(0%) 
Physical examination procedures 23(1.1%) 10(1.14%) 5(1.59%) 5(0.69%) 3(1.7%) 
Pruritus NEC 41(1.96%) 22(2.5%) 3(0.96%) 14(1.94%) 2(1.14%) 
Rashes, eruptions and exanthems NEC 14(0.67%) 7(0.79%) 1(0.32%) 5(0.69%) 1(0.57%) 
Rate and rhythm disorders NEC 4(0.19%) 4(0.45%) 0(0%) 0(0%) 0(0%) 
Rubeola viral infections 1(0.05%) 0(0%) 1(0.32%) 0(0%) 0(0%) 
Salivary gland disorders NEC 2(0.1%) 1(0.11%) 0(0%) 0(0%) 1(0.57%) 
Sensory abnormalities NEC 15(0.72%) 4(0.45%) 0(0%) 10(1.39%) 1(0.57%) 
Site specific vascular disorders NEC 2(0.1%) 0(0%) 2(0.64%) 2(0.28%) 0(0%) 
Skin structures and soft tissue infections 2(0.1%) 0(0%) 0(0%) 0(0%) 0(0%) 
Social issues 1(0.05%) 1(0.11%) 0(0%) 0(0%) 0(0%) 
Soft tissue disorders NEC 2(0.1%) 0(0%) 0(0%) 1(0.14%) 0(0%) 
Speech and language abnormalities 1(0.05%) 0(0%) 0(0%) 1(0.14%) 0(0%) 
Therapeutic and nontherapeutic responses 11(0.53%) 2(0.23%) 3(0.96%) 5(0.69%) 1(0.57%) 
Tongue disorders 1(0.05%) 1(0.11%) 0(0%) 0(0%) 0(0%) 
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Tongue signs and symptoms 1(0.05%) 1(0.11%) 0(0%) 0(0%) 0(0%) 
Tremor (excl congenital) 2(0.1%) 2(0.23%) 0(0%) 0(0%) 0(0%) 
Upper respiratory tract infections 7(0.33%) 1(0.11%) 2(0.64%) 4(0.55%) 0(0%) 
Upper respiratory tract signs and symptoms 4(0.19%) 3(0.34%) 0(0%) 1(0.14%) 0(0%) 
Urinary abnormalities 8(0.38%) 4(0.45%) 1(0.32%) 3(0.42%) 0(0%) 
Urinary tract signs and symptoms NEC 1(0.05%) 0(0%) 0(0%) 1(0.14%) 0(0%) 
Urticarias 2(0.1%) 1(0.11%) 0(0%) 1(0.14%) 0(0%) 
Visual disorders NEC 1(0.05%) 1(0.11%) 0(0%) 0(0%) 0(0%) 
 
Abbreviations: ART: artemisinin; ASAQ: artesunate-amodiaquine; ACT: artemisinin combination therapy; NEC: not elsewhere classified
 
 
 
Dodoo et al. Adverse events in a pharmacovigilance cohort of malaria patients in Ghana 
 
27 
 
Table 4. Events reported grouped by MedDRA® Higher Level Term (HLT) according to age group  
 
 
Total cohort <5 years 5-12 years >12 years 
 
N=2092 N=443 N=219 N=1415 
MedDRA® Higher Level Term n(%) n(%) n(%) n(%) 
Anaemias NEC 1(0.05%) 0(0%) 0(0%) 1(0.07%) 
Anal and rectal signs and symptoms 1(0.05%) 0(0%) 0(0%) 1(0.07%) 
Anxiety symptoms 4(0.19%) 1(0.23%) 0(0%) 3(0.21%) 
Apocrine and eccrine gland disorders 1(0.05%) 0(0%) 0(0%) 1(0.07%) 
Appetite disorders 44(2.1%) 17(3.84%) 5(2.28%) 22(1.55%) 
Asthenic conditions 211(10.09%) 38(8.58%) 15(6.85%) 158(11.17%) 
Bladder and urethral symptoms 4(0.19%) 0(0%) 0(0%) 4(0.28%) 
Bone related signs and symptoms 2(0.1%) 0(0%) 0(0%) 2(0.14%) 
Breast signs and symptoms 1(0.05%) 0(0%) 0(0%) 1(0.07%) 
Breathing abnormalities 4(0.19%) 0(0%) 0(0%) 4(0.28%) 
Cardiac signs and symptoms NEC 10(0.48%) 0(0%) 0(0%) 9(0.64%) 
Circulatory collapse and shock 1(0.05%) 0(0%) 0(0%) 1(0.07%) 
Coughing and associated symptoms 9(0.43%) 6(1.35%) 0(0%) 3(0.21%) 
Dermal and epidermal conditions NEC 6(0.29%) 2(0.45%) 1(0.46%) 3(0.21%) 
Dermatitis and eczema 1(0.05%) 0(0%) 0(0%) 1(0.07%) 
Diarrhoea (excl infective) 25(1.2%) 8(1.81%) 3(1.37%) 14(0.99%) 
Disturbances in consciousness NEC 33(1.58%) 6(1.35%) 4(1.83%) 23(1.63%) 
Disturbances in initiating and maintaining sleep 14(0.67%) 4(0.9%) 1(0.46%) 8(0.57%) 
Dyspeptic signs and symptoms 13(0.62%) 0(0%) 0(0%) 13(0.92%) 
Ear disorders NEC 1(0.05%) 0(0%) 0(0%) 1(0.07%) 
Faecal abnormalities NEC 3(0.14%) 1(0.23%) 0(0%) 2(0.14%) 
Febrile disorders 20(0.96%) 2(0.45%) 3(1.37%) 14(0.99%) 
Feelings and sensations NEC 27(1.29%) 5(1.13%) 0(0%) 22(1.55%) 
Flatulence, bloating and distension 2(0.1%) 0(0%) 0(0%) 2(0.14%) 
Fluid intake decreased 1(0.05%) 0(0%) 0(0%) 1(0.07%) 
Gastrointestinal and abdominal pains (excl oral and throat) 40(1.91%) 2(0.45%) 2(0.91%) 35(2.47%) 
Gastrointestinal atonic and hypomotility disorders NEC 3(0.14%) 1(0.23%) 0(0%) 2(0.14%) 
Gastrointestinal signs and symptoms NEC 7(0.33%) 0(0%) 1(0.46%) 6(0.42%) 
General signs and symptoms NEC 2(0.1%) 2(0.45%) 0(0%) 0(0%) 
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Headaches NEC 65(3.11%) 4(0.9%) 4(1.83%) 57(4.03%) 
Heart rate and pulse investigations 1(0.05%) 0(0%) 0(0%) 1(0.07%) 
Increased physical activity levels 8(0.38%) 0(0%) 0(0%) 6(0.42%) 
Joint related signs and symptoms 3(0.14%) 0(0%) 0(0%) 3(0.21%) 
Lacrimal disorders 2(0.1%) 0(0%) 0(0%) 1(0.07%) 
Mental impairment (excl dementia and memory loss) 1(0.05%) 0(0%) 0(0%) 1(0.07%) 
Migraine headaches 2(0.1%) 0(0%) 0(0%) 2(0.14%) 
Muscle tone abnormalities 1(0.05%) 0(0%) 0(0%) 1(0.07%) 
Muscle weakness conditions 2(0.1%) 0(0%) 0(0%) 2(0.14%) 
Musculoskeletal and connective tissue pain and discomfort 10(0.48%) 0(0%) 1(0.46%) 9(0.64%) 
Musculoskeletal and connective tissue signs and symptoms NEC 1(0.05%) 1(0.23%) 0(0%) 0(0%) 
Nasal congestion and inflammations 1(0.05%) 0(0%) 1(0.46%) 0(0%) 
Nausea and vomiting symptoms 76(3.63%) 24(5.42%) 10(4.57%) 42(2.97%) 
Neurological signs and symptoms NEC 93(4.45%) 2(0.45%) 4(1.83%) 86(6.08%) 
Ocular disorders NEC 5(0.24%) 3(0.68%) 1(0.46%) 1(0.07%) 
Ocular infections, inflammations and associated manifestations 4(0.19%) 3(0.68%) 0(0%) 1(0.07%) 
Oedema NEC 2(0.1%) 0(0%) 0(0%) 1(0.07%) 
Oral soft tissue pain and paraesthesia 4(0.19%) 2(0.45%) 1(0.46%) 1(0.07%) 
Pain and discomfort NEC 30(1.43%) 0(0%) 0(0%) 29(2.05%) 
Paraesthesias and dysaesthesias 1(0.05%) 0(0%) 0(0%) 1(0.07%) 
Physical examination procedures 23(1.1%) 15(3.39%) 4(1.83%) 4(0.28%) 
Pruritus NEC 41(1.96%) 1(0.23%) 4(1.83%) 36(2.54%) 
Rashes, eruptions and exanthems NEC 14(0.67%) 3(0.68%) 1(0.46%) 10(0.71%) 
Rate and rhythm disorders NEC 4(0.19%) 0(0%) 0(0%) 3(0.21%) 
Rubeola viral infections 1(0.05%) 1(0.23%) 0(0%) 0(0%) 
Salivary gland disorders NEC 2(0.1%) 0(0%) 1(0.46%) 1(0.07%) 
Sensory abnormalities NEC 15(0.72%) 0(0%) 0(0%) 15(1.06%) 
Site specific vascular disorders NEC 2(0.1%) 2(0.45%) 0(0%) 0(0%) 
Skin structures and soft tissue infections 2(0.1%) 0(0%) 0(0%) 2(0.14%) 
Social issues 1(0.05%) 0(0%) 0(0%) 1(0.07%) 
Soft tissue disorders NEC 2(0.1%) 0(0%) 1(0.46%) 1(0.07%) 
Speech and language abnormalities 1(0.05%) 0(0%) 0(0%) 1(0.07%) 
Therapeutic and non-therapeutic responses 11(0.53%) 1(0.23%) 4(1.83%) 6(0.42%) 
Tongue disorders 1(0.05%) 0(0%) 0(0%) 1(0.07%) 
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Tongue signs and symptoms 1(0.05%) 0(0%) 0(0%) 1(0.07%) 
Tremor (excl congenital) 2(0.1%) 0(0%) 0(0%) 2(0.14%) 
Upper respiratory tract infections 7(0.33%) 2(0.45%) 0(0%) 5(0.35%) 
Upper respiratory tract signs and symptoms 4(0.19%) 1(0.23%) 0(0%) 3(0.21%) 
Urinary abnormalities 8(0.38%) 3(0.68%) 0(0%) 5(0.35%) 
Urinary tract signs and symptoms NEC 1(0.05%) 0(0%) 1(0.46%) 0(0%) 
Urticarias 2(0.1%) 1(0.23%) 0(0%) 1(0.07%) 
Visual disorders NEC 1(0.05%) 0(0%) 0(0%) 1(0.07%) 
Abbreviations: ART: artemisinin; ASAQ: artesunate-amodiaquine; ACT: artemisinin-combination therapy; NEC: not elsewhere classified
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Table 5. Events (MedDRA®- Preferred Term) reported in under-5’s according to the 
treatment prescribed  
 
Preferred Term 
Total 
N=441
a
 
AQ 
n=70 
Artemether 
n=13 
Artemether +AQ 
n=41 
AS 
n=3 
DHA 
n=61 
DHA + AQ 
n=138 
ASAQ 
n=113 
  n (%)
b
 n (%) n (%) n (%) n (%) n (%) n (%) 
Asthenia 35 3 (4.3) 1 (7.7) 1 (2.4) 1 (33.3) 3 (4.9) 10 (7.2) 16 (14.2) 
Vomiting 24 1 (1.4) 1 (7.7) - - 4 (6.6) 9 (6.5) 9 (8.0) 
Anorexia 17 - - 1 (2.4) - 2 (3.3) 6 (4.3) 8 (7.1) 
Pyrexia 14 2 (2.9) - 1 (2.4) - 2 (3.3) 2 (1.4) 7 (6.2) 
Diarrhoea 8 1 (1.4) - 4 (9.8) - 1 (1.6) 2 (1.4) - 
Cough 6 2 (2.9) - - - 1 (1.6) 2 (1.4) 1 (0.9) 
Feeling of body 
temperature change 4 1 (1.4) - 1 (2.4) - - 1 (0.7) 1 (0.9) 
Headache 4 1 (1.4) - 1 (2.4) - 1 (1.6) - 1 (0.9) 
Insomnia 4 2 (2.9) - - - - 2 (1.4) - 
Sedation 3 2 (2.9) - - - - 1 (0.7) - 
Malaise 2 - - 1 (2.4)  1 (1.6) - - 
Ocular hyperaemia 2 - - 1 (2.4) - - 1 (0.7) - 
Oral pain 2 1 (1.4) - - - - 1 (0.7) - 
Pruritus 2 - - - - - 1 (0.7) 1 (0.9) 
Rash generalised 2 1 (1.4) - - - - 1 (0.7) - 
Pallor 2 - - - - - 2 (1.4) - 
Nasopharyngitis 2 - - - - - 2 (1.4) - 
Abdominal pain upper 1 - - - - - 1 (0.7) - 
Anxiety 1 1 (1.4) - - - - - - 
Crying 1 - - - - - - 1 (0.9) 
Dizziness 1 - - - - - - 1 (0.9) 
Eye swelling 1 - - 1 (2.4) - - - - 
Faeces discoloured 1 - - 1 (2.4) - - - - 
Fatigue 1 1 (1.4) - - - - - - 
Feeling hot 1 1 (1.4) - - - - - - 
Loss of consciousness 1 - - - - - 1 (0.7) - 
Measles 1 -  - - - 1 (0.7) - 
Musculoskeletal 
stiffness 1 - - 1 (2.4) - - - - 
Ocular icterus 1 - - - - - 1 (0.7) - 
Pain of skin 1 - - - - - - 1 (0.9) 
Pharyngolaryngeal pain 1 - - - - - - 1 (0.9) 
Skin discolouration 1 - - - - - 1 (0.7) - 
Somnolence 1 - - - - - 1 (0.7) - 
Urticaria 1 - - - - - - 1 (0.9) 
Weight decreased 1 - - - - - 1 (0.7) - 
aChloroquine (n=1) and DHA + artemether + lumefantrine (n=1) were administered but patients did not report of experiencing any 
AE; b% are percentages of adverse events (n) reported within each treatment group; ASAQ= artesunate-amodiaquine; DHA = 
dihydroartemisinine; AQ = amodiaquine; AS=artesunate 
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Table 6. Event terms reported by patients to the hospital and MedDRA®- Preferred Term. 
 
 
Reported term  
 
Preferred Term 
Total 
N=60 
ASAQ 
n=27 
Non-ASAQ ACTs 
n=5 
Monotherapy 
n=28 
Dizziness Dizziness 17 8 2 7 
Abdominal pain upper Abdominal pain upper 15 11 - 4 
Pyrexia Pyrexia 13 5 - 8 
Vomiting Vomiting 12 2 3 7 
Bodily aches and pains Pain 11 8 - 3 
Headache Headache 10 3 - 6 
Diarrhoea Diarrhoea 9 5 2 2 
Cough Cough 9 3 - 6 
General weakness Asthenia 8 3 2 3 
Rash generalised Rash generalised 7 2 1 4 
Loss of appetite Anorexia 7 2 1 4 
Bitterness in mouth Dysgeusia 4 3 - 1 
Palpitation Palpitation 4 3 - 1 
Nausea Nausea 4 2 - 2 
Insomnia Insomnia 3 1 - 2 
Pruritus Pruritus 3 2 - 1 
Chills Chills 3 3 - - 
Waist pain Myalgia 3 2 - 1 
Yellow-coloured urine Chromaturia 2 - 1 1 
Jaundice Ocular icterus 1 - 1 - 
Numbness of fingers Hypoesthesia 1 1 - - 
Sore mouth Oral pain 1 1 - - 
Tremor Tremor 1 1 - - 
Feeling cold Feeling cold 1 1 - - 
Fainting Loss of consciousness 1 1 - - 
Salivary hypersecretion Salivary hypersecretion 1 - - 1 
Constipation Constipation 1 1 - - 
Chest pains Chest pains 1 1 - - 
Ear pain Ear pain 1 1 - - 
Weight decreased Weight decreased 1 1 - - 
Back pain Back pain 1 1 - - 
